Keeney, Edna http://orcid.org/0000-0002-4763-8891
Sanghera, Sabina
Martin, Richard M.
Gulati, Roman
Wiklund, Fredrik
Walsh, Eleanor I.
Donovan, Jenny L.
Hamdy, Freddie
Neal, David E.
Lane, J. Athene
Turner, Emma L.
Thom, Howard
Clements, Mark S.
Funding for this research was provided by:
Cancer Research UK (C11043/A4286, C18281/A8145, C18281/A11326, C18281/A15064, C18281/A24432)
Article History
Accepted: 5 September 2022
First Online: 6 October 2022
Declarations
:
: RMM is the lead principal investigator (and JLD, FCH and DEN co-PIs) of the CAP trial, funded by Cancer Research UK and the UK Department of Health (C11043/A4286, C18281/A8145, C18281/A11326, C18281/A15064 and C18281/A24432). RMM was supported by a Cancer Research UK (C18281/A29019) programme grant (the Integrative Cancer Epidemiology Programme). RMM is a National Institute for Health Research Senior Investigator (NIHR202411). RMM and HT were supported by the NIHR Biomedical Research Centre at University Hospitals Bristol and Weston NHS Foundation Trust and the University of Bristol. The ProtecT trial is funded by the UK National Institute for Health Research (NIHR) Health Technology Assessment Programme (NIHR HTA: projects 96/20/06, 96/20/99). RG was supported by the National Cancer Institute at the National Institutes of Health (U01 CA253915 and R50 CA221836). HT was supported by a MRC grant MR/S036709/1 for this research. MSC was supported by the Swedish Research Council (through the Swedish eScience Research Centre and project 2018-02526), Prostatacancerförbundet, Karolinska Institutet and Cancerfonden (project CAN 2018/539). The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care.
: EK reports personal consulting fees unrelated to the present work from Pfizer, Roche, Novartis Pharma and BMS. SS reports a postdoctoral fellowship from the NIHR and support for travel from the University of Leeds. JD, RM, ET and EW report receiving grants to their institution from Cancer Research UK. RG reports receiving grants from the National Cancer Institute. HT reports receiving grants to his institution from the UK Medical Research Council, personal consulting fees unrelated to the present work from Pfizer, Roche, BMS, Eisai, Lundbeck, Merck, Novartis Pharma, and Janssen and owns stock in Clifton Insight (consulting company). MC reports receiving funding to his institution from the Swedish Research Council, the Swedish Cancer Society and the Swedish Prostate Cancer Federation.
: Ethical approval was not required.
: Not applicable.
: Not applicable.
: Because of the nature of this research, participants of this study did not agree for their data to be shared publicly, thus supporting data are not available.
: Not applicable.
: EK, SS, RMM, ELT, HT and MSC contributed to the study conception and design. MSC developed the model and assisted with the analyses. EK performed the analyses with guidance from SS, RMM, RG, FW, ELT, HT and MSC. ELW assisted with data provision. The first draft of the manuscript was written by EK and MSC and all authors commented on subsequent versions of the manuscript. All authors read and approved the final manuscript.
: EK affirms that this article is an honest, accurate and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned have been explained.